European Companies Search Engine
EU funding (€4,845,000): Big Data and models for personalized Head and Neck Cancer Decision support Hor1 Jan 2016 EU Research and Innovation programme "Horizon"
Text
Big Data and models for personalized Head and Neck Cancer Decision support
"Cancers of the Head and Neck Region (HNC) are the 6th more deadly cancers worldwide: in Europe ~150.000 new cases are detected and ~70.000 patients die every year. The main reasons for high mortality are the fact that the majority of cases are diagnosed in advanced Stage and the intrinsic heterogeneity of such tumors. At present the only adopted treatment decision method is based on TNM (Tumor-lymph-Nodes-Metastasis) prognostic system, that considers only a few risk factors such as smoking, alcohol abuse and more recently HPV. The TNM system is therefore inadequate to capture the patient-specific biomolecular characteristics of the tumor. HNC treatments can have hard impact on patient’s aesthetics and functionalities and, due to their toxicity, can cause severe morbidity and greatly deteriorate patient’s quality of life. A more precise prognostic prediction than the current TNM system is needed that allows implementing the first-line treatment that maximizes the therapeutic result and minimizes the impacts of therapy. BD2Decide DSS provides clinicians with the ""means"" and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. BD2Decide realizes and validates an Integrated Decision Support System that links population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multiscale prognostic models. Advanced graphical visualization tools are developed for prognostic data disclosure and patient co-participation to the selected treatment. BD2Decide will improve the clinical decision process, uncover new patient-specific patterns that can improve care, and create a virtuous circle of learning. A multicentric clinical study with more than 1.000 patients will be used to validate the system. "
Funded Companies:
| Company name | Funding amount |
| ALL-IN-IMAGE Ltd. | €495,750 |
| Athens Technology Center Anonymi Viomichaniki Emporiki Kai Techniki Etaireia Efarmogon Ypsilis Technologias | €342,000 |
| Azienda Ospedaliero-Universitaria Di Parma | €464,375 |
| Fondazione Irccs Istituto Nazionale DEI Tumori | €815,000 |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €321,375 |
| HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | €338,750 |
| Multimed Engineers Srl | €150,000 |
| Politecnico Di Milano | €308,750 |
| STICHTING AMSTERDAM UMC | €760,938 |
| STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC | €373,063 |
| STICHTING VU | €0.00 |
| Universidad Politecnica de Madrid | €415,000 |
| Universita Degli Studi Di Parma | €60,000 |
Source: https://cordis.europa.eu/project/id/689715
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ALL-IN-IMAGE Ltd. - EU funding (€4,845,000): Big Data and models for personalized Head and Neck Cancer Decision support"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
